8K filed 12/22/2003
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): DECEMBER 22, 2003
-----------------
NOVA BIOGENETICS, INC.
----------------------------------
(Exact name of registrant as specified in its charter)
DELAWARE 1-16703 58-2618895
---------------------------- ---------------- -------------------
(State or other jurisdiction (Commission File (IRS Employer
or incorporation) Number) Identification No.)
8601 DUNWOODY PLACE, SUITE 338, ATLANTA, GEORGIA 30350
------------------------------------------------------------
(Address of principal executive offices, including zip code)
Registrant's telephone number, including area code (770) 650-6508
--------------
N/A
-------------------------------------------------------------
(Former name or former address, if changed since last report)
<PAGE>
ITEM 5. OTHER IMPORTANT INFORMATION
MANAGEMENT
Effective immediately Mr. Tim Moses has been named Sr. Vice President and Chief
operating officer of the company. Dr. Cecil smith has stepped down as interim
CEO and Chairman of the company due to the location difference and to make way
for a new CEO from the Atlanta area. In addition the company has opened up two
positions on the Bio-Pharmaceutical scientific advisory board. These new
openings will be announced at later time as to who has filled these positions.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
NOVA BIOGENETICS, INC.
Dated: DECEMBER 22, 2003 By: /s/ Tim Moses
---------------------------
Tim Moses
Chief Operating Officer
